Abiraterone acetate

(Zytiga®)

Abiraterone acetate

Drug updated on 4/10/2024

Dosage FormFilm-coated tablet (oral; 500 mg); uncoated tablet (oral; 250 mg)
Drug ClassCYP17 inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).
  • Indicated in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Abiraterone acetate (Zytiga) is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) and those with metastatic high-risk castration-sensitive prostate cancer (CSPC).
  • A comprehensive analysis was conducted on 16 systematic reviews/meta-analyses, focusing on Zytiga's safety, effectiveness, and comparative performance against other medications.
  • The risk of cognitive impairment associated with Zytiga use is moderate compared to other novel hormonal agents; it showed a relatively lower risk ratio than enzalutamide but higher than darolutamide.
  • Real-world outcomes indicate similar survival, safety, and economic results between Zytiga and enzalutamide for first-line metastatic CRPC treatment. Evidence suggested improvements in health-related quality of life with abiraterone.
  • In non-metastatic CRPC cases, Zytiga displayed significant efficacy, showing the lowest hazard of metastasis and death compared to placebo and similar medications but had the highest odds of serious adverse events.
  • Efficacy and safety profiles were consistent among Asian patients, suggesting no racial or ethnic limitations in its efficacy or safety profile when treating advanced/metastatic prostate cancer using Zytiga.
  • When combined with prednisolone, Zytiga improved several aspects such as overall survival rates significantly more than ADT alone, indicating its strength in a combination therapy setting, especially for high-risk Non-Metastatic Prostate Cancer.
  • Zytiga administered as first-line treatment followed by enzalutamide has shown significant clinical efficacy according to sequencing studies, which indicates the strategic planning importance during treatments.

Product Monograph / Prescribing Information

Document TitleYearSource
Zytiga (abiraterone acetate) Prescribing Information.2021Janssen Biotech, Inc., Horsham, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta-analysis.2023Clinical and Translational Science
Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: A systematic review.2023Future Oncology
First-line therapy for metastatic castration-sensitive prostate cancer: A network meta-analysis.2022Hong Kong Journal of Radiology
Comparison of treatments for nonmetastatic castration-resistant prostate cancer: Matching-adjusted indirect comparison and network meta-analysis.2022Journal of the National Cancer Institute
Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review.2022Therapeutic Advances in Medical Oncology
Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.2022European Urology
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.2022Lancet
Efficacy and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.2021Frontiers in Oncology
Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.2021Urologic Oncology
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: A systematic review and meta-analysis.2021Prostate Cancer and Prostatic Diseases
Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis.2021Cancer Treatment Reviews
Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis.2021JAMA Oncology
Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review.2021European Eurology Focus
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormoneā€sensitive prostate cancer.2020Cochrane Database of Systematic Reviews
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials.2020Journal of Cancer and Research Therapeutics
Longitudinal model-based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer.2020European Journal of Clinical Pharmacology
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.2019Urology

Clinical Practice Guidelines

Document TitleYearSource
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.2023Journal of the National Comprehensive Cancer Network
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents.2023Annals of Oncology
2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2022Canadian Urological Association
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.2022European Society for Medical Oncology
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update.2021Journal of Clinical Oncology
Consensus on the treatment and follow-up for metastatic castration-resistant prostate cancer: A report from the first global prostate cancer consensus conference for developing countries.2021American Society of Clinical Oncology
What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.2021European Urology Focus
Advanced prostate cancer: AUA/ASTRO/SUO guideline.2020American Urological Association
Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2020Annals of Oncology
Prostate Cancer, version 2.2019.2019Journal of the National Comprehensive Cancer Network